Loading...
Indian Pharmaceutical Exporter · #6 for Ibrutinib · $29.2K export value · DGFT Verified
Rmpl Pharma LLP is the #6 Indian exporter of Ibrutinib with $29.2K in export value and 25 verified shipments. Rmpl Pharma LLP holds a 2.9% market share in Ibrutinib exports across 3 countries. The company exports 13 pharmaceutical products worth $438.6K across 3 therapeutic categories.
| JAMAICA | $32.7K | 16 | 3.6% |
| GRENADA | $28.5K | 2 | 3.2% |
| LEBANON | $28.1K | 18 | 3.1% |
| CHILE | $27.6K | 34 | 3.1% |
| KENYA | $21.6K | 21 | 2.4% |
| UNITED ARAB EMIRATES | $17.3K | 26 | 1.9% |
India exports Ibrutinib to 60 countries. The top destination is BRAZIL (59.8%), followed by UKRAINE and TURKEY.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE, | BRAZIL | $142.8K | 39 |
| VALTER LUIZ CACHELLI | BRAZIL | $70.8K | 2 |
| ACI LOGISTICS DWC LLC | UKRAINE | $55.8K | 2 |
| TO THE | BRAZIL | $47.5K | 13 |
| SKIN LINE LOGISTIC | IRAQ | $30.6K | 15 |
| INVOICE RAISED TO | UNITED ARAB EMIRATES | $29.5K | 5 |
| DIRCE CANDIDA DA SILVA | BRAZIL | $17.7K | 3 |
| TO THE CONCERN PERSON | BRAZIL | $15.1K | 5 |
| JACINTO FERREIRA DA SILVA | BRAZIL | $11.3K | 2 |
| MANOEL JOAQUIM DA SILVA | BRAZIL | $9.8K | 3 |
India's Ibrutinib is purchased by 210 buyers worldwide. The top buyer is TO THE, (BRAZIL), followed by VALTER LUIZ CACHELLI and ACI LOGISTICS DWC LLC.
India exported $701.8K worth of Ibrutinib through 560 shipments from 103 suppliers to 60 countries, serving 210 buyers globally. Rmpl Pharma LLP contributes $29.2K to this total, accounting for 2.9% of India's Ibrutinib exports.
Rmpl Pharma LLP's average Ibrutinib shipment value is $1.2K per consignment, based on 25 shipments totaling $29.2K.
Rmpl Pharma LLP ranks #6 among 103 Indian Ibrutinib exporters with a 2.9% market share. The top 3 exporters are NIVIRA EXPORTS ($239.9K), VAMA LIFECARE PRIVATE LIMITED ($203.2K), RBN MEDITECH PRIVATE LIMITED ($41.7K). Rmpl Pharma LLP processed 25 shipments to 3 destination countries.
What Rmpl Pharma LLP must comply with to export Ibrutinib to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | SHREE KRISHNA LIFECARE | $32.7K | 16 | 1 | $2.0K |
| 5 | MEDIGEN PHARMA | $29.7K | 3 | 2 | $9.9K |
| 6 | RMPL PHARMA LLP ★ | $29.2K | 25 | 3 | $1.2K |
| 7 | RAVI PHARMA | $25.3K | 5 | 1 | $5.1K |
| 8 | JPC GLOBAL | $20.9K | 23 | 3 | $910 |
Rmpl Pharma LLP ranks #6 among 103 Indian Ibrutinib exporters. Average shipment value of $1.2K compared to the market average of $6.8K. The closest competitors by value are SHREE KRISHNA LIFECARE and MEDIGEN PHARMA.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 202 | 36.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 185 | 33.0% |
| Bombay Air | 40 | 7.1% |
| DELHI AIR CARGO ACC (INDEL4) | 24 | 4.3% |
| DELHI AIR | 20 | 3.6% |
| Bombay Air Cargo | 19 | 3.4% |
| AHEMDABAD AIR | 11 | 2.0% |
| HYDERABAD AIR | 11 | 2.0% |
Rmpl Pharma LLP also exports these advanced oncology products. Each links to the detailed product page.
Rmpl Pharma LLP exports 13 products worth $438.6K. Beyond Ibrutinib, top products include Lenalidomide, Rituximab, Daratumumab, Cladribine, Dacarbazine. View the complete Rmpl Pharma LLP profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Ibrutinib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 60+ countries, 210+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Rmpl Pharma LLP's Ibrutinib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Rmpl Pharma LLP
Full Company Profile →
13 products · $438.6K total trade · 3 categories
Access shipment-level records, pricing trends, and buyer contacts for Rmpl Pharma LLP.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ibrutinib. For current shipment-level data, contact TransData Nexus.